Navigation Links
Anesiva Announces First Quarter 2008 Financial Results
Date:5/8/2008

opedic surgery patients is pain following the procedure even when treated with opioids. In fact, the second and third most common complaints are the nausea and vomiting caused by the very opioids taken to manage pain. Adlea addresses the need for improved post-surgical pain management by providing a locally administered alternative without the side effects of systemic opioids and other standard pain medications. There are approximately 4.5 million orthopedic surgeries and arthroscopic procedures each year in the U.S., according to the American Academy of Orthopedic Surgeons.

Recent Highlights and Accomplishments

Anesiva continued its commercialization efforts for the second quarter launch of Zingo and to advance Adlea in Phase 3 trials:

Zingo

-- In preparation for the Zingo U.S. launch in June 2008, Anesiva's

hospital-based sales force expanded its efforts to educate nurses and

physicians on the importance of treating the pain associated with IV

starts and blood draws and on the features and use of Zingo for their

pediatric patients. The Anesiva sales force is working with the sales

force of co-promotion and distribution partner Sagent Pharmaceuticals,

Inc., whose efforts are targeted at the hospital pharmacists critical

to gaining inclusion on drug formularies.

-- To grow the potential Zingo market, in March Anesiva submitted a

supplemental New Drug Application (sNDA) with the U.S. Food and Drug

Administration (FDA) to expand the indication for Zingo to include the

treatment of pain associated with peripheral IV insertions and blood

draws in adults. In U.S. hospitals, there are approximately 245 million

adult peripheral venous access procedures performed annually.

-- In line with the company's goal of establishing Zingo as a global

brand, Anesiva expanded the exclusive licensing and distribution


'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 02, 2014 The inventors of ... for chronic tinnitus are seeking support for development costs ... Indiegogo platform ( http://igg.me/at/tinaway ), was launched on September ... therapeutic ‘mHealth’ app and is based on ten years ... team of biomedical and software engineers, Dr. Ian Dixon ...
(Date:8/31/2014)... PARSIPPANY, N.J. , Aug. 31, 2014 ... New Drug Discovery program in Anti-Infective research when two ... the coveted Qualified Infectious Disease Product (QIDP) status from ... granted to drugs which act against pathogens which have ... and are identified by Centre for Disease Control (a ...
(Date:8/30/2014)... (PRWEB) August 31, 2014 The ... a professional and in-depth study on the current ... Global and China. , The report provides a ... and industry chain structure. Global market analysis and ... focus on history, developments, trends and competitive landscape ...
(Date:8/29/2014)... According to a new market report published by ... was valued at USD 3,754.6 million in 2012 and is ... a CAGR of 5.9% from 2013 to 2019. , Nearly ... afflicted by bone and joint disorders, and this number is ... and will continue to increase the demand for orthobiologics. Other ...
Breaking Biology Technology:tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... Inc. (NYSE Amex: CUR ) announced it ... develop its human neural stem cell technology for the ... "Research to Treat Cancerous Brain Tumors with Neural Stem ... Investigator John Zhang, MD, PhD, Professor of Neurosurgery, Loma ...
... that attacks the small intestines of humans and animals ... can fight disease and aid in military operations. ... engineering, at the University of Tennessee, Knoxville, and his ... attachment of the microorganism Giardia. Giardia causes one of ...
... Informex , the leading meeting place for buyers ... introduction of a new conference, ,Business Strategies for ... to be hosted October 5-6th, 2011 in Boston, ... topics regarding the future of pharma, sourcing strategies ...
Cached Biology Technology:Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 3UT professor's pathogen research inspires robotics design for medicine and military 2New Conference Offers Solutions for Success in the Growing Biologics Market 2New Conference Offers Solutions for Success in the Growing Biologics Market 3
(Date:9/2/2014)... suggests that professional baseball pitchers with poor core stability are ... single season because of injury than are pitchers who have ... , In the study, 347 pitchers were assessed for lumbopelvic ... pelvis as they raised a leg to step up were ... 30 days cumulative, not consecutive during the season ...
(Date:9/2/2014)... If you think losing weight is enough to prevent Type ... report in September 2014 issue of The FASEB ... overweight to develop Type 2 diabetes. This study compared genetically ... a fast-food meal, the circulating metabolites, including those related to ... same levels. These findings suggest that the onset of ...
(Date:9/2/2014)... (September 2, 2014) In the battle between our ... unknown ally in bacteria-killing viruses known as phages. In ... Hospital, Partners In Health, Haiti,s National Public Health Laboratory, ... to give up their virulence in order to survive. ... found that cholera,s mutational escape from phage predation ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3What you eat and not just the number of calories, is a significant factor in diabetes risk 2War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3
... Long touted as an energy-saving alternative for home ... to be even more efficient, as well as dimmable, ... by householders as a longer-lasting, energy efficient alternative to ... the power and last 1,000 times longer than incandescent ...
... and her colleagues have identified a specific DNA change ... in some people. It provides a potential mechanism that ... consistent with the growing trend of personalized medicine. ... issue of the American Journal of Psychiatry ...
... used as live bait for freshwater fishing. With ... channel catfish and other freshwater fishes. They may ... in bait shops in Arizona, Colorado and New Mexico ... a chytrid fungus called Batrachochytrium dendrobatidis (Bd). "These ...
Cached Biology News:Queen's researchers shine light on compact fluorescent bulb problems 2Altered gene can increase risk of schizophrenia 2Altered gene can increase risk of schizophrenia 3Spring fishing season arrives... and with it, amphibian diseases 2Spring fishing season arrives... and with it, amphibian diseases 3
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
... CGH Genomic Labeling Systems are a high-performance ... genomic DNA samples for array-based Comparative Genomic ... direct labeling formats, the BioPrime Plus Array ... solution to your genomic labeling needs. ...
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
... PBL's bioassays for interferons are cytopathic effect ... assays. Sample types include; tissue culture supernatents; ... In these assays, one unit is defined as ... reduce the cytopathic effect of viral infection by ...
Biology Products: